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Parkes Weber syndrome, vein of Galen aneurysmal
malformation, and other fast-flow vascular anomalies are caused
by RASA1 mutations
Abstract
Capillary malformation-arteriovenous malformation (CM-AVM) is a newly recognized autosomal
dominant disorder, caused by mutations in the RASA1 gene in six families. Here we report 42 novel
RASA1 mutations and the associated phenotype in 44 families. The penetrance and de novo occurrence
were high. All affected individuals presented multifocal capillary malformations (CMs), which represent
the hallmark of the disorder. Importantly, one-third had fast-flow vascular lesions. Among them, we
observed severe intracranial AVMs, including vein of Galen aneurysmal malformation, which were
symptomatic at birth or during infancy, extracranial AVM of the face and extremities, and Parkes Weber
syndrome (PKWS), previously considered sporadic and nongenetic. These fast-flow lesions can be
differed from the other two genetic AVMs seen in hereditary hemorrhagic telangiectasia (HHT) and in
phosphatase and tensin homolog (PTEN) hamartomatous tumor syndrome. Finally, some CM-AVM
patients had neural tumors reminiscent of neurofibromatosis type 1 or 2. This is the first extensive study
on the phenotypes associated with RASA1 mutations, and unravels their wide heterogeneity.
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ABSTRACT 
Background Mutations in RASA1 have been documented in 6 families (39 individuals) with autosomal 
dominant multifocal capillary malformations (CMs). Nine individuals had an associated arteriovenous 
malformation/fistula (AVM/AVF). One patient had Parkes Weber syndrome, a disorder considered to 
be sporadic and non-genetic. We investigated the RASA1 involvement in a large series of patients with 
CM and fast-flow vascular lesions. 
Methods We collected clinical information and DNA samples for 61 probands and their families with 
a phenotype similar to that observed in the original study: 56 had multifocal CMs, and 35 also had a 
fast-flow anomaly: 16 Parkes Weber syndrome and 19 either an AVM or an AVF; 5 had Parkes Weber 
syndrome without multifocal CMs. RASA1 was screened by DHPLC followed by sequencing.   
Results We identified 42 distinct mutations in 44/61 probands: 13/16 with Parkes Weber syndrome, 
16/19 with AVM/AVF, 15/21 with multifocal CMs only, and 0/5 with Parkes Weber syndrome 
without multifocal CMs. Fifty-seven relatives also had a RASA1 mutation. Overall, 17 individuals with 
RASA1 mutations had an AVM/AVF: 8 intracerebral, 2 of which were vein of Galen aneurysmal 
malformations. In addition, several CMs demonstrated fast-flow on hand-held Doppler. Moreover, 6 
patients had either benign or malignant tumors, 3 of which are known to occur in neurofibromatosis. 
Penetrance was 98% and de novo occurrence was 32%.   
Conclusions Multifocal CM is the hallmark of RASA1 mutation. These patients often have extra- or 
intracerebral AVM/AVFs, confirming the original association designated capillary malformation-
arteriovenous malformation (CM-AVM). In addition, Parkes Weber syndrome with multifocal CMs is 
a genetic disease, part of CM-AVM spectrum. Furthermore, specific neural tumors may also be linked 
to RASA1.  
INTRODUCTION 
Recognition of the association Capillary Malformation-ArterioVenous Malformation (CM-
AVM; OMIM 608354) was the culmination of the research for a gene responsible for inherited 
capillary stains. Several affected families guided linkage studies and led to the identification of 
germline mutations in the RASA1 gene in 6 families (39 individuals) 1, 2. These capillary 
malformations (CMs) were noted to be atypical in what they were multifocal, small, round-to-oval, 
pinkish-to-red, and randomly distributed. Interestingly, 9/35 affected individuals had either an 
arteriovenous malformation (AVM) or an arteriovenous fistula (AVF): 2 in the central nervous system 
and 7 elsewhere (Table 1). The high frequency of fast-flow vascular malformations raised the concern 
about their possible presence in asymptomatic patients with harmless cutaneous capillary stains. As 
the latter occur with a birth prevalence of 0.3%, it is important to recognize those patients who have an 
elevated risk for cutaneous or visceral fast-flow lesions. AVMs are the most difficult-to-treat vascular 
anomalies in any location, and intracerebral lesions can cause hemorrhagic stroke, hydrocephalus or 
cognitive impairment.  
One of the affected family members in the original study (Table 1) was diagnosed as having 
Parkes Weber syndrome (OMIM 608355), a fast-flow vascular disorder characterized by a cutaneous 
vascular stain with multiple arteriovenous fistulas and overgrowth of the affected extremity 3. This 
condition, described in 1918 by Parkes Weber 4, has always been considered to be one of the sporadic 
overgrowth syndromes. Most of these are of unknown etiology, although they have been hypothesized 
to be non-genetic or caused by somatic mosaicism. The phenotypic similarity among these disorders 
often leads to misdiagnosis and improper management.  
In this study, we set out to evaluate the types and frequency of fast-flow lesions associated 
with RASA1 mutations, as well as the possible genetic basis of Parkes Weber syndrome.  
MATERIAL AND METHODS  
Patient Recruitment  
Twenty-one centers located in the European Union, North and South America, and Australia 
participated in this study. Informed consent was obtained from all participating subjects, and the 
research protocol was approved by the ethics committee of the medical faculty of Université 
catholique de Louvain, Brussels, Belgium. Inclusion criteria were multifocal CMs, with/without a fast-
flow lesion, including Parkes Weber syndrome. Individuals with Parkes Weber syndrome without 
multifocal CMs were also included. The patients were examined by participating dermatologists, 
surgeons or geneticists who completed a questionnaire with inquiries regarding family history, age at 
appearance of vascular anomalies, as well as type, location, number, color, size, symptoms, associated 
anomalies, and  radiological investigations by Doppler-ultrasonography, magnetic resonance imaging 
(MRI), and/or selective angiography. A proband was the first affected individual in a family. We 
recruited 61 probands, and 120 family members. Fifty-seven probands were Caucasian (Europe, 
Canada, USA, Australia) and 4 were Hispanic.  
Mutation Analysis of the RASA1 Gene  
DNA was extracted from peripheral leukocytes or buccal cells using the PUREGENE blood 
kit (Gentra Systems, Minneapolis, MN, USA). To amplify all the 25 exons of the RASA1 gene, 
including exon-intron boundaries (Ensemble Gene ID ENSG00000145715), 26 sets of primers were 
designed. Genomic DNA was screened by denaturing high-performance liquid chromatography 
(DHPLC) on the WAVE 3500 HS system (Transgenomic Inc., Omaha, NE, USA). For each sample 
that showed an abnormal elution profile, the PCR product was purified using the Qiagen PCR 
purification columns (Qiagen) and sequenced on a CEQ2000 fluorescent capillary sequencer 
(Beckman Coulter). DHPLC was used to assess co-segregation of the abnormal elution profile with 
the phenotype. Mutations were named according to international recommendations 
(http://www.genomic.unimelb.edu.au/mdi/mutnomen/). Numbering of nucleotides was based on the 
cDNA sequence NM_002890.1 with the adenosine of the ATG start codon marked as +1.  
 
RESULTS 
Genetic studies 
Among the 61 probands, 56 had multifocal CMs. Nineteen patients had an associated 
AVM/AVF, 21 had multifocal CMs only, and 16 patients Parkes Weber syndrome. The 5 other 
probands had isolated Parkes Weber syndrome (without multifocal CMs). A germline mutation was 
identified in 44/56 probands with CMs: 16/19 (84%) of those with AVM/AVF, 15/21 (71%) of those 
with CMs only, and 13/16 (81%) of those with Parkes Weber syndrome. Twenty-four patients had 
sporadic CMs, whereas 32 had at least one clinically affected relative (Table 2). The genetic basis was 
ascertained in 14/24 (58%) of the sporadic and 30/32 (93.7%) of the familial patients. Forty-one of the 
probands with RASA1 mutation were Caucasian and 3 Hispanic. No mutation was identified in the 5 
patients with isolated Parkes Weber syndrome: 3/5 were sporadic and 2 had at least one first degree 
relative with a classical single CM. 
By genotyping relatives of the 44 probands with a RASA1 mutation, 57 individuals were 
detected with a RASA1 mutation, increasing the total number of affected to 101 (58% females, 42% 
males). All mutations co-segregated with the vascular anomalies and were absent in 200 control 
chromosomes. There were only two unaffected carriers (F26 and F27) and 3 phenocopies with a 
classical single CM (F10 and two in F37) (Table 2).  
We identified 42 distinct RASA1 mutations: 39 were novel and private, two (c.2125C>T; 
c.1279C>T) were novel and found in 2 apparently unlinked families, and one (c.1336C>T) was 
previously published (Table 2; Figure 1) [Eerola, 2003 #2]. The genetic alterations consisted of 19 
insertions or deletions that caused a frame-shift, or a splice-site alteration, and 23 substitutions: 14 
nonsense, 7 splice-site, and 2 missense mutations distributed in 15 of the 25 exons (Figure 1). The two 
substitutions, p.Y426C and p.E763V, involved conserved amino acids, and occurred in the second 
SH2 domain, and in the RasGAP domain, respectively. Fourteen (32%) were de novo mutations. There 
was no difference among the distribution of de novo vs. the inherited mutations in the gene.  
Clinical spectrum in patients with a RASA1 mutation 
The clinical penetrance was 98% (99/101) among individuals with a RASA1 mutation. The 
most prominent feature was the presence of small, usually multifocal, and randomly distributed 
cutaneous CMs (Figure 2).The number of CMs varied from 1 to 53. Ninety patients had multifocal 
CMs, and 9 had a single atypical CM (Table 1). One individual had a CM on the tongue. Some of the 
lesions were present at birth, other appeared later, in childhood. Many CMs were smaller than 1cm in 
diameter; but some were larger, up to 15 cm. Typically, they were pink, sometimes red, brown or grey. 
A narrow, white halo was present in some of the CMs. Some were warm, but without a thrill, and 
continuous wave hand-held Doppler examination revealed an increased flow in many of the lesions. In 
16 families (41 individuals), only multifocal CMs were observed. Fast-flow anomalies (Parkes Weber 
syndrome, AVM or AVF) were present in 32.6% of the investigated patients (33 of 101)  
Parkes Weber syndrome  
Parkes Weber syndrome with multifocal CMs was the clinical diagnosis in 16 patients from 13 
families with a RASA1 mutation, with two affected individuals per family in 3 cases (Tables 1&2). The 
Parkes Weber anomaly was localized in the upper extremity in 6 patients (3 left, 3 right), and in the 
lower extremity in 10 patients (5 left, 5 right). The entire extremity was involved in 10/16, whereas in 
the other 6 patients, the lesion was confined to only part of the limb. In some patients, the ipsilateral 
buttock or the thoracic region was also affected (Figure 2). These patients exhibited the typical 
unilateral large capillary stain, bony and soft-tissue hypertrophy, with the affected limb being longer 
and/or larger than the unaffected one. The cutaneous stains were diffuse, pink to red, warm, and 
usually without a thrill. No venous or lymphatic components were observed clinically. The vascular 
lesions were present at birth and worsened with age; ischemia was not documented. Reduced hair-
density was seen in some adult patients in the area of the capillary stain. Five patients had cardiac 
hypertrophy (31%) due to the fast-flow, particularly if the lower extremity was involved. In four 
patients the fast-flow was well tolerated, but one patient required medical treatment for cardiac failure.   
Arteriovenous malformation / arteriovenous fistula (AVM/AVF) 
Eighteen AVMs associated with multifocal CMs were identified in 15 individuals with a 
RASA1 mutation in 14 families (Tables 1&2).  In one family, 2 individuals had an AVM, and in 
another one, 2 individuals had either an AVM or a Parkes Weber syndrome. Eight AVMs were facial: 
nose (n=2), right cheek (n=4), right ear (n=1), and nose-lip-cheek (n=1). The location of the AVM was 
variable: cutaneous, subcutaneous, and sometimes with muscular and bony involvement. All but one 
AVM was first noted at birth, one appeared during adolescence. Six AVMs were intra-cerebral: one 
asymptomatic pial lesion and five symptomatic lesions: two vein of Galen aneurysmal malformations, 
causing cardiac failure at birth, and death in one infant; one intracranial lesion (where ?? Morgan 
Bruce) causing late onset seizures; one left frontal lesion with hydrocephalus; one lesion in the 
posterior fossa, causing hemorrhage, epilepsy and cardiac failure. The extra-cerebral location of AVM 
included thorax, and buttock (each n=1). One patient had AVM of mediastinum, arm, and nose. This 
patient also had non-small cell lung cancer of the mediastinum and died at age 38 years from massive 
hemoptysis. Two individuals had an AVF: one asymptomatic pial lesion, and another, left temporal 
AVF causing epilepsy soon after birth, hydrocephaly and delayed development.  
Radiological investigation of fast-flow lesions  
Angiographic features of the extra-cerebral AVMs included slight enlargement and tortuosity 
of the feeding arteries, tissue “blush” with arteriolovenous or arteriovenular microfistulas and dilated 
draining veins (Figure 2). There were no aneurysms or varices. The intracranial AVMs had imaging 
features consistent with the location (e.g. pial, hemispheric, Galenic). Patients with Parkes Weber 
syndrome had diffuse blush and microshunting throughout extensively involved muscle groups and 
areas of subcutaneous fat. Some muscles were uninvolved. The deep and superficial veins were 
dilated.  
MRI of extra-cerebral AVMs and Parkes Weber syndrome showed overgrowth of affected 
muscle with mild hypersignal on T2-weighted sequences, and contrast enhancement, along with 
variable degrees of thickening of the subcutaneous fat (Figure 2). Bony hypertrophy was common, but 
intraosseous AVM was not seen.  
Other clinical features 
Other infrequent clinical features are shown in Table 1&2. Cardiac structural defects were detected in 
4 patients: atrial septal defect, pulmonary valvular stenosis and persistent ductus arteriosus; tetralogy 
of Fallot; atrial septal defect secundum or persistent foramen ovale; pulmonary valvular stenosis (each 
n=1). Interestingly, 6 individuals had various tumors i.e., an optic glioma, a neurofibroma, a vestibular 
schwannoma, a non-small cell lung tumor, a superficial basal cell carcinoma, or a paraspinal adipose 
tissue lesion. Chylous ascities was observed in one patient, and ectopic thyroid and parathyroids in one 
patient. 
Clinical phenotype of patients without a RASA1 mutation 
No mutation in RASA1 was found in 12 probands (2 familial and 10 sporadic) with a phenotype 
indistinguishable from those with mutation. The clinical data of these probands plus 6 familial 
members are detailed in Table 2. All had multifocal CMs, and 6/18 a fast-flow lesion: 3 had Parkes 
Weber syndrome and 3 had an AVM. No mutation in RASA1 was found in 5 patients with Parkes 
Weber syndrome without multifocal CMs. Moreover, the Parkes Weber anomaly was less 
hypertrophic, darker, and sometimes staining was bilateral. No significant radiological differences 
were observed by MRI and/or angiography between the lesions of individuals with or without a 
RASA1 mutation.  
DISCUSSION 
Multifocal and atypical CM is the cardinal feature of patients with RASA1 mutations 
confirming our earlier data (Eerola et al. 2003). We have now identified a total of 140 individuals with 
a RASA1 mutation; 95.7% had these peculiar CMs (Table 1). Although a minority of affected 
individuals had only one atypical CM, most have multifocal lesions, and new lesions often arose 
during childhood. Some of the lesions had a pale halo and/or slightly increased flow by hand-held 
Doppler examination. Perhaps these could be considered pre-AVM, yet they remain stable throughout 
adulthood. These pathognomonic multifocal CMs have to be differentiated from punctuate, radiate or 
arborising telangiectatic lesions seen in hereditary benign telangiectasia (HBT; OMIM 187260) and 
hereditary hemorrhagic telangiectasia (HHT; OMIM 187300). One family initially reported to have 
HBT 5 had, in fact, CM-AVM and a RASA1 mutation (F11 in this study). 
This study also showed that patients with Parkes Weber phenotype with multifocal CMs 
elsewhere on the body have a genetic disease, due to de novo or parental mutations in RASA1. Of 
individuals with RASA1 mutation 12% had Parkes Weber syndrome (Table 1), and one third of them 
developed cardiac overload or failure, underlying the importance for cardiac evaluation in these 
patients. Thus, Parkes Weber syndrome is a clinically and molecularly heterogeneous entity, i.e. 
isolated forms are not caused by mutations in RASA1 and seem to be less hypertrophic, darker, and 
sometimes bilateral. Nevertheless, no striking radiological differences were observed by MRI and/or 
angiography between the lesions of individuals with or without RASA1 mutation. In our series, Parkes 
Weber syndrome with multifocal CMs was 4 times more frequent than isolated Parkes Weber 
syndrome (20 vs. 5 cases). Therefore, at least two Parkes Weber syndrome entities can now be 
separated, allowing study of differences in evolution, prognosis, incidence, and management. 
Additionally, these two forms must be differentiated from Klippel-Trenaunay syndrome (KTS; OMIM 
149000). One family previously reported to have KTS with autosomal dominant inheritance has, in 
fact, CM-AVM and a RASA1 mutation (Family 27 in our study) 6.  
CM-AVM patients are also at risk for intra- or extra-cranial AVM and AVF. In our two 
studies, 18.5% of individuals with a RASA1 mutation had such lesions: 7.1% intra-cerebral and 11.4% 
extra-cerebral (Table 1). This figure might be an underestimation, as cerebral imaging was performed 
mainly in symptomatic patients. Symptomatic AVMs were not found in other internal organs. 
Interestingly, we also discovered that vein of Galen aneurysmal malformation, a rare cerebral AVM of 
unknown etiology, is caused by mutations in RASA1, and thus it too is a genetic anomaly. Since both 
of our patients were sporadic, de novo mutations in genes involved in angiogenesis may be important 
in the ethiopathogenesis of other seemingly sporadic vascular anomalies. As asymptomatic 
AVM/AVF lesions are likely present in CM-AVM patients, a radiological protocol for follow-up and 
management is needed. The use of cranial MRI as a screening tool in patients with multiple CMs 
would seem to be a reasonable precaution. 
The radiological features of extracerebral fast-flow lesions in our patients (AVM or Parkes 
Weber syndrome) differ from those in two other familial conditions, hereditary hemorrhagic 
telangiectasia and Bannayan-Riley-Ruvalcaba / Cowden Syndrome. In the former, AVMs or AVFs 
predominately affect the viscera and brain, and frequently consist of AVF or arteriolovenous fistulae 
with prominent varices of the immediate draining vein. In the latter, fast-flow lesions are usually 
intramuscular, often multifocal and are associated with ectopic fat and severe disruption of tissue 
architecture. The angioarchitecture usually consists of arteriolvenous fistulae, with irregular varices of 
the immediate draining veins. 
We could not identify any RASA1 alterations in 12 patients with indistinguishable CM-AVM 
phenotype. This could be explained by the limitations in the sensitivity of the techniques used, gross 
rearrangement within the gene, or alterations in the promoter, deeper in introns, or in regulatory 
regions. Another gene could also be involved. The localized nature, the number of vascular anomalies 
and the intrafamilial variability suggest that a somatic second-hit might be necessary for a lesion to 
develop. This mechanism has been shown in two other inherited multifocal vascular malformations: 
one patient with glomuvenous malformation and one with cerebral cavernous malformation 7, 8. In 
addition, a second-hit was identified in an AVM of a patient with “Proteus-like” syndrome 9 
We have now identified 50 CM-AVM families on 3 continents, seven of which (45 affected 
individuals) were found in the French speaking part of Belgium with a population of 4 million 
inhabitants 1 and this study. Thus, one can estimate a minimum prevalence of 1/100,000 for CM-AVM 
in Caucasians. This translates roughly to 48,000 and 30,000 affected individuals in the European 
Union and the United States, respectively. Based on the association of fast-flow lesions with RASA1 
alterations, it is very important to recognize these particular multifocal CMs, as the clue to the 
diagnosis.  
The molecular mechanisms by which mutations in the RASA1 gene lead to the vascular 
phenotype are unknown. Most of the mutations are predicted to be truncating because of frame-shift or 
nonsense alterations, with the most 5’ mutation being in exon 1. This suggests loss-of-function. 
Neither the type nor the position of the mutation correlated with the phenotype. Of interest for 
diagnostic screens, one fifth of the mutations occurred in exon 19.  
The protein encoded by RASA1, p120RasGAP, is an inhibitor of Ras, which controls cellular 
growth, proliferation, survival and differentiation. Moreover, independently from Ras, p120RasGAP 
enhances the Akt activity, protecting rat cardiac myocytes against 10, and interacts with p190RhoGAP 
to direct cell movement 11. In Rasa1-/- murine embryonic cells, PDGF induces a high Ras activated 
level and prolonged MAP kinase activation 12. Whatever the mechanism, the importance of 
p120RasGAP for vascular development is underscored by the vascular phenotype observed in Rasa1-/- 
murine embryos 13.  
An increased risk of tumors in CM-AVM would be expected, as increased Ras activation has 
been observed in different tumors 14 and somatic RASA1 missense mutations have been identified in 
basal cell carcinoma 15. Although the number of tumors in our series was low, the cellular types are of 
interest (Table 2). Among the six identified, one was a basal cell carcinoma, and 3 others were tumors 
of the nervous system. One of these was a neurofibroma, and another an optic glioma; both tumors can 
be isolated or occur in neurofibromatosis type I, which is caused by mutations in NF1, a RASA1 
homologue. Interestingly, AVM can be associated with neurofibromatosis type I  16 17 18. The third 
patient had a vestibular schwannoma, the annual incidence is about 1/60,000 of the population 19 but it 
is characteristic of neurofibromatosis type II. Although the cellular expression of RASA1 has not been 
completely elucidated, these observations suggest some possible overlapping functions between the 
proteins encoded by RASA1, NF1 and NF2. Thus, RASA1 could be involved in some patients with 
neurofibromatosis without a known germline or a somatic second-hit mutation. Another patient 
developed a non-small cell lung cancer at a relative young age (around 30 years), and another patient 
had an asymptomatic paraspinal adipose lesion.  
In conclusion, we demonstrated RASA1 to be important angiogenic factor frequently mutated 
in patients with pathognomonic pinkish-red CMs and often associated other fast-flow vascular 
anomalies. We also demonstrated that Parkes Weber syndrome and vein of Galen aneurysmal 
malformation, in association with multifocal CMs, are genetic disorders, caused by RASA1 mutations. 
Frequent occurrence of de novo RASA1 mutations underscores the need for genetic screening in 
patients with sporadic vascular anomalies. Interestingly, some patients had neural tumors reminiscent 
of neurofibromatosis.   
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Figure 1 Schematic representation of the RASA1 gene and CM-AVM causing mutations. Exons 
(boxed) and introns (simple lines) are drawn to scale, except for intron 1 (longer than shown); 
untranslated regions, small boxes. Known domains of the p120-RasGAP protein marked below exons. 
Mutations in bold were described previously (Eerola et al. 2003). Mutations associated with PKWS 
are underlined. Mutations associated with AVM/AVF are indicated by a star.  
Figure 2 Phenotypic variation in capillary malformation-arteriovenous malformation (CM-AVM). A, 
Parkes Weber syndrome in the upper or lower extremity. Note reduced hair-density in the area of the 
capillary stain on the thoracic region. B,  multifocal capillary malformations; arrowhead, with halo. C, 
AVM on nose or right cheek. D, Imaging of a patient with an AVM on right cheek: axial T1 (fat-sat.) 
weighted image after contrast infusion showed diffuse thickening (cheek, maxilla and hard palate 
(arrows)) and increased enhancement. Selective arteriography of right facial artery (lateral view): 
enlargement of the feeding artery, diffuse alteration of arteriolar and capillary bed. 
Figure 3 Signaling pathways implicating p120RasGAP.  
Growth factors, cytokines or hormones bind to tyrosine-kinase receptors and induce their dimerization 
followed by cross-phosphorylation of tyrosine residues in their cytosolic domains. This activates Ras-
Raf-Mek-Erk pathway leading to cell differentiation, proliferation and migration, and the PI3K/AKT 
pathway leading to cell survival. P120RasGAP down-regulates Ras signaling by accelerating the 
conversion of active Ras (GTP-bound) to an inactive form (GDP-bound). P120RasGAP interacts with 
p190RhoGAP and directs the orientation of migration. P120RasGAP binds to and enhances the activity 
of Akt, protecting cells from apoptosis. 
Table 1 Clinical characteristics of patients with CM-AVM: current study and our previous study 
(Eerola et al. 2003) 
Table 2  
a  Phenotypes of individuals with CM-AVM with or without RASA1 mutation.  
b RASA1 germline mutations  
c Nucleotide numbering according to NM_002890.1 with the adenosine of the ATG start codon 
marked as +1.  
d Mutations named according to international recommendations 
(http://www.genomic.unimelb.edu.au/mdi/mutnomen/). 
I: families with RASA1 mutation.  
II: families without RASA1 mutation 
CO: Cardiac Overload; CF: Cardiac Failure; VV; TOF: Tetralogy of Fallot; PDA: Patent Ductus 
Arteriosus; ASD: Atrial Septal Defect; PFO: Patent Foramen Ovale; P St: Pulmonary Stenosis 
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Table 1 
current study 
(N=101)
previous study      
(N = 39)
total         
(N = 140)
no. of patients no. of patients no. (%)
affected 99 35 134 (95,7)
multifocal CMs 90 35 125 (89,3%)
single atypical CM 9 0 9 (6,4%)
AVM /AVF 17 9 26 (18.5%)
intra-cerebral (vein of Galen aneurysmal malformation) 8 (2) 2 10 (7.1%)
extra-cerebral 9 7 16 (11.4%)
Parkes Weber syndrome 16 1 17 (12,1)
Other
cardiac anomalies 4 0 4 (2,8%)
benign / malignant tumors 6 0 6 (4,2%)
chylous ascites 1 0 1 (0,7%)
ectopic thyroid and parathyroids 1 0 1 (0,7%)
Arnold Chiari malformation 1 1 2 (1.4%)
Clinical characteristics of  140 patients with CM-AVM
     Table 2 
Family
No. 
mutation 
carriers
CM AVM/ AVF PWS Symptoms and associated features 
Nucleotide 
change (c,d)
Amino acid 
change (d)
I. 1 4 4 0 0 optic glioma; paraspinal adipose lesion c.613delCTTAT p.L205fs
2 1 1 0 0 c.656C>G p.S219X
3 1 1 0 1 CO c.806delTTTAC p.L269fs
4 1 1 1 0 c.828+3A>T splicing
5 1 1 0 0 c.951insG p.M318fs
6 2 2 0 1 CO c.957G>A p.W319X
7 6 6 0 2 CO c.1017+1G>T  splicing
8 2 2 1 0 epilepsy; hydrocephaly c.1192C>T p.R938X
9 1 1 1 0 c.1208insC p.T404fs
10 8 9 0 0 c.1277A>G p.Y426C
11 2 2 0 0 c.1279C>T p.R427X
12 1 1 1 0 c.1279C>T p.R427X
13 4 4 0 0 c.1332+5G>A splicing
14 1 1 0 1 c.1336C>T p.Q446X
15 3 3 0 2 c.1350insT p.N451fs
16 1 1 0 0 c.1362insTCAGT p.D455fs
17 2 2 0 1 c.1480insT p.L493fs
18 1 1 1 0 c.1490T>G p.L497X
19 4 4 0 1 CO; TOF, superficial basal cell carcinoma c.1575insATGT p.S526fs
20 1 1 1 0 c.1636C>T p.Q546X
21 1 1 1 0 CF; epilepsy; hemorrhages; ASDII/PFO c.1683insCT  p.P562fs
22 2 2 0 1 P St c.1698+3insT splicing
23 2 2 1 0 c.1870C>T p.Q624X
24 3 3 0 0 c.2026C>T p.Q676X
25 5 5 1 1 VV c.2125C>T p.R709X
26 6 5 0 2 CF c.2125C>T p.R709X
27 4 3 0 1 PDA, ASD, P St, prolapsed tricuspid valve c.2184+1delG splicing
28 1 1 0 0 c.2185-1G>A splicing
29 1 1 1 0 CF; died rapidly after birth c.2288A>T p.E763V
30 2 2 1 0 hydrocephaly c.2341G>T p.E781X
31 3 3 2 0 c.2365 C>T p.R789X
32 2 2 0 1 c.2422 C>T p.Q808X
33 2 2 1 0 c.2450delCT p.S817fs
34 2 2 0 0 c.2488-2A>G   splicing
35 1 1 1 0 non-small cell lung cancer; hemoptysis c.2488-1delGTTA splicing
36 1 1 0 0 c.2514insA p.N838fs
37 2 4 1 0 CF c.2532delTTTAA p.L845fs
38 1 1 1 0 ectopic thyroid and parathyroid c.2579delTCAT p.F860fs
39 2 2 0 0 chylous ascities c.2603+1G>A splicing
40 2 2 0 0 ureteral reflux, epispadias c.2603+2insT splicing
41 3 3 0 0 c.2603+4insA splicing
42 1 1 0 1 neurofibromas c.2603+5G>T splicing
43 3 3 0 0 vestibular schawanomma c.3028 C>T R1010X
44 2 2 0 0 c.3052delG p.A1018fs
II. 45 7 0 1
46 1 1 0
47 1 0 0
48 1 0 0
49 1 0 1
50 1 0 1
51 2 0 0
52 1 1 0
53 1 0 0
54 1 0 0
55 1 1 0
56 1 0 0
Phenotype (a) Mutation (b)
no mutation identified
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